Ocuphire Pharma : Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update - Form 8-K

Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update


Building Momentum with Completion of Patient... | March 24, 2022

Related Keywords

United States ,San Antonio ,Texas ,American ,James Katz ,David Boyer ,Inder Paul Singh ,Paul Karpecki ,David Lally ,David Brown ,Mina Sooch ,Peter Kaiser ,Mitchell Jackson ,Douglas Devries ,Michaelj Allingham ,Corey Davis ,Y Ralph Chu ,Ocuphire Pharma ,Jay Pepose ,Exchange Commission ,Company Annual Report On Form ,American Academy Of Ophthalmology ,Clinical Development ,Nasdaq ,Ocuphire Pharma Inc ,Ocuphire Announces Financial Results ,Fourth Quarter ,Year Ended ,Provides Corporate Update ,Patient Enrollment ,Stage Trials ,Late Stage Clinical Trial Data Catalysts ,Expected End ,Retinopathy Results Expected ,Mydriasis Planned ,Potential Launch ,First Dilation Reversal Drop ,Nyxol Alone ,Low Dose Pilocarpine ,Medical Advisor ,Board Member ,Medical Advisory Board ,Drug Application ,Vision Disturbances ,Nyxol Phase ,Diabetic Macular Edema ,Recent Business Highlights ,Investor Rd Day ,Key Opinion Leaders ,Typeb End ,Degeneration Conference ,Telling It Like Is Conference ,Gender Equality ,Life Sciences Investment ,Lifesci Partners Corporate Access ,Neovascular Eye Disease ,From Biology ,Special Issue ,Molecular Activity ,International Journal ,Therapeutic Candidates ,Age Related Macular ,Annual Scientific Meeting ,American Society ,Retina Specialists ,Diabetic Retinopathy ,Year Ended December ,Annual Report ,Private Securities Litigation Reform Act ,Consolidated Statements ,Comprehensive Loss ,Quarter Ended ,Nc Stock Exchange ,News ,Information ,Press Release ,Cuphire ,Nnounces ,Financial ,Results ,Or ,The ,Fourth ,Quarter ,End ,Ear ,Nded ,021 ,Rovides ,Corporate ,Building ,Momentum ,Ith ,Completion ,F Ocup Us67577r1023 ,